COMMUNIQUÉS West-GlobeNewswire

Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
05/05/2026
Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual Global Embolization [...]
FibroBiologics CEO Issues Letter to Shareholders
05/05/2026
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
05/05/2026
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
05/05/2026
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a [...]
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
05/05/2026
Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026 Updated data from Phase 2 study of DISC-0974 in patients with anemia of [...]
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
05/05/2026
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on [...]
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
05/05/2026
Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval Steady-state pharmacokinetic findings provide mechanistic support for previously [...]
Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
05/05/2026
Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to enhance scale, [...]
Sofwave Medical Reports First Quarter Fiscal 2026 Financial Results and Business Highlights
05/05/2026
First quarter revenue of $24.4M, +46% year-over-year growth; IFRS gross margin of 75.0% First quarter usage fee revenue of $11.0M, +56% year-over-year growth IFRS and non-IFRS net income of $1. 3 M and $1. 7 M versus [...]
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026
05/05/2026
SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization [...]
SS Innovations Surpasses 10,500 Surgeries Performed with the SSi Mantra Surgical Robotic System
05/05/2026
FORT LAUDERDALE, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII) , a developer of innovative surgical robotic technologies dedicated to making [...]
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
05/05/2026
SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, [...]
Ocugen Provides Business Update with First Quarter 2026 Financial Results
05/05/2026
Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p<0.05) 31% reduction in [...]
Clene Announces $7 Million Underwritten Offering of Common Stock
05/05/2026
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage [...]
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
05/05/2026
Vancouver, Canada, May 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Cellution Biologics Celebrates Expansion of U.S. Headquarters in Roswell, Georgia
05/05/2026
Ribbon Cutting Ceremony to Mark Continued Growth and Investment in U.S. Operations ROSWELL, Ga., May 05, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc., a regenerative medicine company focused on advancing human- [...]
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
05/05/2026
-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: [...]
Precision Optics Announces Receipt of $3.5 Million Follow-On Production Order for Single-Use Ophthalmic Program
05/05/2026
Order supports customer’s full launch, with shipments expected to commence shortly and be fulfilled over 12 -15 months LITTLETON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI [...]
Bicycle Health Expands Leadership Team to Increase Access to Evidence-Based Opioid Use Disorder Care
05/05/2026
Dr. Travis Schamber Promoted to Chief Medical Officer; Jennifer Haas Named Chief Marketing Officer; Shay Hurst Named Chief People Officer ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Bicycle Health , the nation’s leading [...]

Pages